Oral tolerance.
Faria AM, Weiner HL.
Immunol Rev. 2005 Aug;206:232-59. doi: 10.1111/j.0105-2896.2005.00280.x.
Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
Li ZJ, He B, Domenichini A, Satiaputra J, Wood KH, Lakhiani DD, Bashaw AA, Nilsson LM, Li J, Bastow ER, Johansson-Percival A, Denisenko E, Forrest AR, Sakaram S, Carretero R, Hämmerling GJ, Nilsson JA, Lee GY, Ganss R.
J Clin Invest. 2024 Sep 17;134(18):e179860. doi: 10.1172/JCI179860.
Mechanisms of oral tolerance.
Garside P, Mowat AM.
Crit Rev Immunol. 1997;17(2):119-37. doi: 10.1615/critrevimmunol.v17.i2.10.
Contact tolerance.
Steinbrink K, Pior J, Vogl T, Sorg C, Macher E.
Pathobiology. 1999;67(5-6):311-3. doi: 10.1159/000028087.
Defective Central Immune Tolerance Induced by High-Dose D-Galactose Resembles Aging.
Du HM, Wang YJ, Liu X, Wang SL, Wu SM, Yuan Z, Zhu XK.
Biochemistry (Mosc). 2019 Jun;84(6):617-626. doi: 10.1134/S000629791906004X.
Tolerance during dosing with H2-receptor antagonists. An overview.
Wilder-Smith CH, Merki HS.
Scand J Gastroenterol Suppl. 1992;193:14-9. doi: 10.3109/00365529209096000.
Ionizing radiation and the immune response.
Anderson RE, Warner NL.
Adv Immunol. 1976;24:215-335. doi: 10.1016/s0065-2776(08)60331-4.
Oral tolerance: therapeutic implications for autoimmune diseases.
Faria AM, Weiner HL.
Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57. doi: 10.1080/17402520600876804.
Tissue levels of glyceryl trinitrate and cGMP after in vivo administration in rat, and the effect of tolerance development.
Torfgård K, Ahlner J, Axelsson KL, Norlander B, Bertler A.
Can J Physiol Pharmacol. 1991 Sep;69(9):1257-61. doi: 10.1139/y91-184.
Dose-dependent tolerance to ozone. I. Tracheobronchial epithelial reorganization in rats after 20 months' exposure.
Plopper CG, Chu FP, Haselton CJ, Peake J, Wu J, Pinkerton KE.
Am J Pathol. 1994 Feb;144(2):404-20.
